Ronak Desai
Internal Medicine · Greer, SCNPI 1154620987
Payments from drug & device makers
Across 115 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$438
- Novo Nordisk$251
- Johnson & Johnson$232
- Medtronic$169
- AstraZeneca$152
- Boehringer Ingelheim$146
- plus $724 from 13 others
What the payments were for
- Food & beverage$2,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $438 |
| Novo Nordisk | 14 | $251 |
| Johnson & Johnson | 7 | $232 |
| Medtronic | 1 | $169 |
| AstraZeneca | 8 | $152 |
| Boehringer Ingelheim | 12 | $146 |
| AbbVie | 8 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $125 |
| Novartis | 8 | $107 |
| Scilex Pharmaceuticals Inc. | 4 | $68 |
| Pfizer | 5 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| GSK | 3 | $39 |
| Astellas Pharma US Inc | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Merck | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xultophy 100/3.6$128
- Repatha$106
How this compares
$2,112 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $32,582 |
| JardianceEmpagliflozin | 68 | $25,677 |
| PradaxaDabigatran Etexilate Mesylate | 109 | $24,031 |
| EliquisApixaban | 31 | $18,972 |
| Spiriva RespimatTiotropium Bromide | 47 | $18,763 |
| Wixela InhubFluticasone Propion/Salmeterol | 53 | $14,771 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 33 | $14,157 |
| Humulin NInsulin Nph Human Isophane | 39 | $8,395 |
| Victoza 2-PakLiraglutide | 12 | $7,626 |
| Atorvastatin Calcium | 542 | $6,878 |
| Gabapentin | 181 | $4,558 |
| Levothyroxine Sodium | 240 | $4,501 |
| Lisinopril | 357 | $4,471 |
| AlvescoCiclesonide | 33 | $4,357 |
| Losartan Potassium | 292 | $4,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa, Spiriva Respimat | $146 | $68,471224 claims |
| Novo NordiskOzempic | $251 | $32,58244 claims |
| PfizerEliquis | $59 | $18,97231 claims |
| Lilly USA, LLCHumulin N | $14 | $8,39539 claims |
| GSKArexvy | $39 | $1,61711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Greer
- William EllisonGreer$192K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.